We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Alpha 1-antitrypsin (AAT) deficiency
- My disclosures of significant relationships
- A registry of patients with AAT deficiency
- Primary objective of the registry
- American thoracic society documents
- AAT: history
- First description of AAT deficiency
- Dr. Eriksson and Dr. Stoller
- Medline citations for the term AAT deficiency
- Epidemiology of AAT deficiency
- Prevalence of AAT deficiency
- Prevalence of PI*Z AAT deficiency
- AAT deficiency is frequently undiagnosed
- Most with AAT deficiency escape detection
- Alpha 1-antitrypsin deficiency is under-recognized
- A1AT-deficient readers survey of alpha 1 news (1)
- A1AT-deficient readers survey of alpha 1 news (2)
- Diagnostic delay interval by year of diagnosis
- Trends in diagnosing AAT deficiency
- Physiology of AAT and pathophysiology
- Physiology of AAT
- Structure of the AAT molecule (1)
- Alpha-1 antitrypsin molecule
- Function of the AAT molecule (1)
- Function of the AAT molecule (2)
- Structure of the AAT molecule (2)
- Mechanism of loop-sheet polymerization
- Polymer of Z-type alpha 1-antitrypsin molecules
- Liver biopsy
- Genetics of alpha-1 antitrypsin deficiency
- Protective threshold serum value
- Alpha 1-antitrypsin deficiency serum levels
- Clinical features of AAT deficiency (1)
- Clinical features of AAT deficiency (2)
- Design of the AAT deficiency registry
- Cumulative enrollment in AAT deficiency registry
- AAT deficiency registry: Sex and race
- AAT deficiency registry: Age
- AAT deficiency registry: Employment
- AAT levels by phenotype
- Lung functions test results
- FEV1 percent of predicted normal
- Self reported medical history of patients
- AAT deficiency registry: Symptom history
- Smoking accelerates onset of dyspnea
- FEV1 percent of predicted by smoking
- Natural history of AAT deficiency
- 30 year follow-up of AAT deficient individuals (1)
- 30 year follow-up of AAT deficient individuals (2)
- 32 year follow-up of AAT deficient individuals (1)
- 32 year follow-up of AAT deficient individuals (2)
- FEV1 slope values by smoking status
- Natural history of AAT deficiency (PI*ZZ)
- AAT deficiency registry: Overall mortality
- Mortality rate by initial percent predicted
- Underlying causes of death
- Death causes among never smokers with AAT
- Diagnosis of AAT deficiency
- Classic chest radiograph
- A cut from the upper chest
- A lower cut from the chest
- Clinical features that should prompt suspicion (1)
- Clinical features that should prompt suspicion (2)
- Recommendations for AAT testing (1)
- Recommendations for AAT testing (2)
- Recommendations for AAT testing (3)
- Treatment of AAT deficiency
- Efficacy criteria for augmentation therapy
- Therapy for alpha 1-antitrypsin deficiency
- Studies of efficacy of augmentation therapy
- Efficacy of intravenous augmentation therapy (1)
- Efficacy of intravenous augmentation therapy (2)
- Efficacy of intravenous augmentation therapy (3)
- Conclusions of clinical efficacy of augmentation (1)
- Conclusions of clinical efficacy of augmentation (2)
- New and emerging treatments for AAT (1)
- New and emerging treatments for AAT (2)
- ATT: conclusions (1)
- ATT: conclusions (2)
Topics Covered
- Epidemiology
- Pathophysiology
- Clinical testing
- Clinical features
- Natural history
- Therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stoller, J. (2012, September 9). Alpha-1 antitrypsin deficiency: state of the art [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/EEBY1176.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jamie Stoller, Consultant: Talecris/Grifols, Baxter, CSL Behring, Kamada ; Other: Have given grand rounds lectures supported by Takecris/Grifols, CSL Behring, Baxter.